Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Notified -
Globe Newswire19-02-2025, 19:05
King Faisal Specialist Hospital and Research Centre Seeks to Achieve Self-Sufficiency in Radiopharmaceuticals in the Kingdom 30-10-2023, 21:45